$CHRS

2 stories mentioning CHRSUpdated just now

Every FINWIRES story that references CHRS, newest first.

What are analysts saying about CHRS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

Coherus OncologyInitiatedSell3h ago

What's the latest news on CHRS?

Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets

Coherus Oncology (CHRS) said Wednesday it has begun the process to sell remaining assets related to its former biosimilars business.The assets include patents and other intellectual property, royalties, cell lines, and related materials, the company said.The company said Oppenheimer will serve as its financial advisor for the sale.Shares of the company were down 3.2% in Wednesday trading.Price: $1.26, Change: $-0.04, Percent Change: -3.15%

$CHRS

Wire91d ago

Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics

Coherus Oncology (CHRS) said Tuesday it has entered a clinical collaboration and supply deal with Zumutor Biologics to conduct a phase 1 trial of ZM008 in combination with LOQTORZI.The trial will enroll up to 45 patients in the US with solid tumors, including colorectal, head and neck, and non-small cell lung cancers, to evaluate safety, tolerability, and dosing, the company said.Under the agreement terms, Coherus will provide LOQTORZI to trial sponsor Zumutor, while both companies will retain all commercial rights to their respective compounds, it added.Price: $1.49, Change: $+0.01, Percent Change: +0.34%

$CHRS

Track with the FINWIRES app suite

FolioX

Track CHRS in your portfolio

WheelAI

Analyze CHRS options with the wheel strategy

StockInsider

See market sentiment on CHRS